Hopefully they will be testing our Leronlimab S

Quote:

---

Hopefully they will be testing our Leronlimab

---

Some comments on Leronlimab for Coronavirus after the communication from CYDY (most of them extracted from the paper "Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag" in reference below:

http://dx.doi.org/10.1101/2020.01.30.927871doi

"Recent research on the spike glycoprotein of the 2019-nCoV (the new Wuhan Coronavirus) to understand its evolution, sequence and structural features using computational tools was undertaken:"

Some conclusions are relevant to us:

1) The amino acid sequence presents 4 insertions (an insertion is a modification in the “normal” amino genomic sequence) of that are not present in other coronaviruses analyzed
2) Surprisingly, each of the four inserts aligned with short segments of the Human immunodeficiency Virus-1 (HIV-1) proteins
3) The first 3 inserts aligned to short segments of amino acid residues in HIV-1 gp120 (glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope), the insert 4 aligned to HIV-1 Gag. Gag , or group specific antigen, is the major structural protein of HIV-1 and all other retroviruses and comprises about 50% of the mass of a viral particle.
4) It is unlikely that all 4 inserts in the 2019-nCoV spike glycoprotein fortuitously match with 2 key structural proteins of an unrelated virus (HIV-1) .
5) The novel inserts are part of the receptor binding site of 2019-nCoV

Gag protein of HIV is involved in host membrane binding, packaging of the virus and for the formation of virus-like particles. Gp120 plays crucial role in recognizing the host cell by binding to the primary receptor CD4 (CD4 receptor binding is the most obvious step in HIV infection). This binding induces structural rearrangements in GP120, creating a high affinity binding site for a chemokine co-receptor like CXCR4 and/or CCR5 .

Therefore Leronlimab, a CCR5 antagonist being able to bind to gp120 will block cell-binding capabilities and, arguably, help the host to fight the disease.

Yes, they should be testing our Leronlimab !!!